Mixed Data for Sanofi/REGN's REGN88 - Zacks.com

Mixed Data for Sanofi/REGN's REGN88 Zacks.com While one study (MOBILITY) evaluated patients with rheumatoid arthritis (RA) the other (ALIGN) evaluated ankylosing spondylitis (AS) patients. Sarilumab is an antibody targeting the interleukin-6 receptor (IL-6R). The data from the RA trial was ... Sanofi, Regeneron report positive phase II b trial results with sarilumab in ...pharmabiz.com Sanofi, Regeneron reveal Phase 2b sarilumab trials resultsPharmaceutical Business Review Sanofi/Regeneron's sarilumab shines for RA, fails in ASPharma Times Zenopa all 11 news articles »

Sanofi eyes phase III move for sarilumab in rheumatoid arthritis - InPharm

Sanofi eyes phase III move for sarilumab in rheumatoid arthritis InPharm In the phase IIb MOBILITY trial rheumatoid arthritis patients treated with sarilumab and standard RA treatment methotrexate (MTX), saw a significant improvement in signs and symptoms compared to MTX alone. “Following these encouraging phase IIb results ... Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in ...PR Newswire (press release) Positive results in Sanofi RA trialPMLiVE all 55 news articles »

Zalicus: Undervalued, With Strong Pipeline Potential - Seeking Alpha

Zalicus: Undervalued, With Strong Pipeline Potential Seeking Alpha Zalicus announced it has initiated a phase 2b clinical trial evaluating Synavive for the treatment of rheumatoid arthritis (RA). The trial, SYNERGY (SYNavivE for Reducing signs and sYmptoms of rheumatoid arthritis trial), is a 12-week, 5-arm, ... and more »

Zalicus Initiates SYNERGY Trial - Zacks.com

Zalicus Initiates SYNERGY Trial Zacks.com by Jason Napodano, CFA Zalicus (ZLCS - Analyst Report) announced it has initiated a phase 2b clinical trial evaluating Synavive for the treatment of rheumatoid arthritis (RA). The trial, SYNERGY (SYNavivE for Reducing signs and sYmptoms of rheumatoid ... Zalicus Initiates SYNERGY TrialDaily Markets all 3 news articles »